BridgeBio Oncology Therapeutics, Inc.
BBOTHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeBridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and. At a $685.7M market cap, BridgeBio Oncology Therapeutics, Inc. ranks as a small-cap company within healthcare. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models.
Market Cap
$685.7M
Beta
0.39
P/E (TTM)
—
P/E (Fwd)
-4.06
EPS (TTM)
$-1.92
EPS (Fwd)
$-2.11
ROE
-62.2%
ROA
-37.2%
Cash
$252.3M
Total Debt
$2.6M
Free CF
-$86.1M
52W Change
-20.4%
Annual Financials
Cash vs Debt
BridgeBio Oncology Therapeutics, Inc. holds $252.3M in cash against $2.6M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$86.1M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -62.2%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With a beta below 0.7, BridgeBio Oncology Therapeutics, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence BridgeBio Oncology Therapeutics, Inc.'s trajectory.